Expert RA upgraded PROMOMED DM's credit rating to ruA
16.03.2022
16.03.2022
Promomed Group of Companies will continue to invest in the development of Biochemistry's Saransk sites. About 7.5 billion rubles will be invested in 2022. This was stated by Peter Bely, Chairman of the Board of Directors of Promomed Group of Companies, which includes the Saransk Biochemist plant, during a meeting with Artem Zdunov, Head of RM.

He noted that the plant is actively developing. At the moment, three large industrial facilities are being built, among them one of the facilities that will provide synthesis of active pharmaceutical substances.
"We are still leaders in the production of antiviral medicines, including for the treatment of coronavirus infection and its consequences,– said the director of the company.
The company pays great attention to the development of drugs for the treatment of cancer, human immunodeficiency virus, and coronavirus.
Artyom Zdunov noted the high importance of the company's modernization of production facilities and the development of new sites. He also expressed gratitude to the director of the enterprise for the charitable assistance provided during the fight against the pandemic.
Source: www.mordovmedia.ru
SourcesStay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office